Regulatory Filings • Jul 15, 2009
Regulatory Filings
Open in ViewerOpens in native device viewer
Nantes (France) & Booxmer (Netherlands) – July 15th , 2009− VIVALIS (NYSE Euronext: VLS) and INTERVET/SCHERING-PLOUGH ANIMAL HEALTH today announced the signing of a commercial license, based on the letter of intent signed in 2008, to use the EB66® cell line, a VIVALIS proprietary technology, for the production of a veterinary vaccine. Moreover, through this agreement, INTERVET/SCHERING-PLOUGH ANIMAL HEALTH is also granted rights to test the EB66® cell line for the production of 12 different pathogens.
"VIVALIS is pleased to enter into this new agreement with INTERVET/SCHERING-PLOUGH ANIMAL HEALTH, a worldwide leader in animal health vaccines. This agreement highlights that the EB66® cell line became a new industry standard for the production of vaccines." said Franck Grimaud, VIVALIS CEO.
Terms of the agreement were not disclosed.
EB66® cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium.
The BMF (Biologics Master File) for the registration of the EB66® cell line with the FDA (U.S. Food and Drug Administration) was filed June 27, 2008.
EB66® cell line is currently used or tested by 75% of the major players in vaccines. With 27 licenses already signed, the EB66® cell line is becoming a new standard cell substrate for biologics production.
**********************
VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:
The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.
The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.
The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL Kaketsuken, Merial, Intervet Schering Plough, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.
Learn more about Vivalis at www.vivalis.com
VIVALIS Listed on Euronext Paris – Compartment C of NYSE Euronext Reuters: VLS.PA – Bloomberg: VLS FP Included in NYSE Euronext's Next Biotech index
VIVALIS NewCap Franck Grimaud, CEO Financial communication Agency
Email: [email protected] Steve Grobet / Emmanuel Huynh Tel.: +33 (0) 1 44 71 94 91 Email:[email protected]
Intervet/Schering-Plough Animal Health is focusing on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative animal health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. For more information about Intervet/Schering-Plough Animal Health visit the following website: www.intervet.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.